Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Axel Hoos, Ira Gupta, Veronique Bragulat, Zangdong He, Joanna B. Opalinska, Adam D. Cohen

ABSTRACT

Interim analyses of a phase I study with GSK2857916, an antibody-drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM). We provide updated safety and efficacy results of the BMA117159 trial following an additional 14 months' follow-up. This open-label, first-in-human, phase I study was conducted at nine centres in the USA, Canada and the UK, and included adults with MM and progressive disease after stem cell transplantation, alkylators, proteasome inhibitors, and immunomodulators. In part 1, the recommended dose of 3.4 mg/kg was identified; in part 2, patients received GSK2857916 3.4 mg/kg once every 3 weeks. Selected part 2 safety/tolerability and efficacy endpoints are reported. Twenty-one (60.0%; 95% confidence interval (CI) 42.1-76.1) of 35 patients achieved partial response or better, including two stringent complete responses and three complete responses. The median progression-free survival was 12 months and median duration of response was 14.3 months. Thrombocytopenia and corneal events were commonly reported; no new safety signals were identified. GSK2857916 was well tolerated and demonstrated a rapid, deep and durable response in heavily pre-treated patients with relapsed/refractory MM, consolidating the interim analyses conclusions that GSK2857916 is a promising treatment for these patients. More... »

PAGES

37

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41408-019-0196-6

DOI

http://dx.doi.org/10.1038/s41408-019-0196-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112880630

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30894515


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Princess Margaret Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.415224.4", 
          "name": [
            "Princess Margaret Cancer Centre, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trudel", 
        "givenName": "Suzanne", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cornell University", 
          "id": "https://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA", 
            "Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lendvai", 
        "givenName": "Nikoletta", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Health Service", 
          "id": "https://www.grid.ac/institutes/grid.451052.7", 
          "name": [
            "NIHR/University College London Hospital Clinical Research Facility, NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Popat", 
        "givenName": "Rakesh", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Levine Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.468189.a", 
          "name": [
            "Levine Cancer Institute, Atrium Health, Charlotte, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voorhees", 
        "givenName": "Peter M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reeves", 
        "givenName": "Brandi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Libby", 
        "givenName": "Edward N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana-Farber Cancer Institute, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richardson", 
        "givenName": "Paul G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GSK, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoos", 
        "givenName": "Axel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GSK, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gupta", 
        "givenName": "Ira", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GSK, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bragulat", 
        "givenName": "Veronique", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GSK, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "He", 
        "givenName": "Zangdong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GSK, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Opalinska", 
        "givenName": "Joanna B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania", 
          "id": "https://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Adam D.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1506348", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002559520"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.20031330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002726623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.14145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007909090"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2422", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018678117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-10-535088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018796721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/nyas.13038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021804241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2008.402", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028476811", 
          "https://doi.org/10.1038/leu.2008.402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2010-10-299487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029457945"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2016.388", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037474750", 
          "https://doi.org/10.1038/leu.2016.388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2012.09241.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044999235"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/jop.2015.0064", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059285427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084601874"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2017.138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086041207", 
          "https://doi.org/10.1038/leu.2017.138"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.25359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104240051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.15_suppl.8007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106715820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30576-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109823387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30576-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109823387"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "Interim analyses of a phase I study with GSK2857916, an antibody-drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM). We provide updated safety and efficacy results of the BMA117159 trial following an additional 14 months' follow-up. This open-label, first-in-human, phase I study was conducted at nine centres in the USA, Canada and the UK, and included adults with MM and progressive disease after stem cell transplantation, alkylators, proteasome inhibitors, and immunomodulators. In part 1, the recommended dose of 3.4\u2009mg/kg was identified; in part 2, patients received GSK2857916 3.4\u2009mg/kg once every 3 weeks. Selected part 2 safety/tolerability and efficacy endpoints are reported. Twenty-one (60.0%; 95% confidence interval (CI) 42.1-76.1) of 35 patients achieved partial response or better, including two stringent complete responses and three complete responses. The median progression-free survival was 12 months and median duration of response was 14.3 months. Thrombocytopenia and corneal events were commonly reported; no new safety signals were identified. GSK2857916 was well tolerated and demonstrated a rapid, deep and durable response in heavily pre-treated patients with relapsed/refractory MM, consolidating the interim analyses conclusions that GSK2857916 is a promising treatment for these patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/s41408-019-0196-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1045682", 
        "issn": [
          "2044-5385"
        ], 
        "name": "Blood Cancer Journal", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Antibody\u2013drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study", 
    "pagination": "37", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d7e590022e3cb949c344077c15f2dbc187151c32556ce77ec0054bbd94ab8605"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30894515"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101568469"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41408-019-0196-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112880630"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41408-019-0196-6", 
      "https://app.dimensions.ai/details/publication/pub.1112880630"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78935_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/s41408-019-0196-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0196-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0196-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0196-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0196-6'


 

This table displays all metadata directly associated to this object as RDF triples.

221 TRIPLES      21 PREDICATES      46 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41408-019-0196-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ne628ea020d484189a3306e842ba5dcd1
4 schema:citation sg:pub.10.1038/leu.2008.402
5 sg:pub.10.1038/leu.2013.313
6 sg:pub.10.1038/leu.2016.388
7 sg:pub.10.1038/leu.2017.138
8 https://doi.org/10.1016/s1470-2045(18)30576-x
9 https://doi.org/10.1056/nejmoa1506348
10 https://doi.org/10.1084/jem.20031330
11 https://doi.org/10.1089/jop.2015.0064
12 https://doi.org/10.1093/annonc/mdx096
13 https://doi.org/10.1111/bjh.14145
14 https://doi.org/10.1111/j.1365-2141.2012.09241.x
15 https://doi.org/10.1111/nyas.13038
16 https://doi.org/10.1158/1078-0432.ccr-12-2422
17 https://doi.org/10.1182/blood-2010-10-299487
18 https://doi.org/10.1182/blood-2013-10-535088
19 https://doi.org/10.1200/jco.2018.36.15_suppl.8007
20 https://doi.org/10.18632/oncotarget.25359
21 schema:datePublished 2019-04
22 schema:datePublishedReg 2019-04-01
23 schema:description Interim analyses of a phase I study with GSK2857916, an antibody-drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM). We provide updated safety and efficacy results of the BMA117159 trial following an additional 14 months' follow-up. This open-label, first-in-human, phase I study was conducted at nine centres in the USA, Canada and the UK, and included adults with MM and progressive disease after stem cell transplantation, alkylators, proteasome inhibitors, and immunomodulators. In part 1, the recommended dose of 3.4 mg/kg was identified; in part 2, patients received GSK2857916 3.4 mg/kg once every 3 weeks. Selected part 2 safety/tolerability and efficacy endpoints are reported. Twenty-one (60.0%; 95% confidence interval (CI) 42.1-76.1) of 35 patients achieved partial response or better, including two stringent complete responses and three complete responses. The median progression-free survival was 12 months and median duration of response was 14.3 months. Thrombocytopenia and corneal events were commonly reported; no new safety signals were identified. GSK2857916 was well tolerated and demonstrated a rapid, deep and durable response in heavily pre-treated patients with relapsed/refractory MM, consolidating the interim analyses conclusions that GSK2857916 is a promising treatment for these patients.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N11752d75c70f49648c53b331b9d69cdc
28 N1536c36f27f24752bb129edd7a4c6b63
29 sg:journal.1045682
30 schema:name Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
31 schema:pagination 37
32 schema:productId N05012ff274d8437e91e7550a439b576f
33 N7c70ca36b163492880686d8982e24383
34 N86cf05e2233f4e128467535b377b9e37
35 Na6ecd2d8796840228ac8cc5bfc3534ef
36 Nb7031f635c9e4cc2ac7d4d2946e327a7
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112880630
38 https://doi.org/10.1038/s41408-019-0196-6
39 schema:sdDatePublished 2019-04-11T13:17
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher Nb80875ec3c4d4bb5bc969678ecce7e8f
42 schema:url https://www.nature.com/articles/s41408-019-0196-6
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N05012ff274d8437e91e7550a439b576f schema:name pubmed_id
47 schema:value 30894515
48 rdf:type schema:PropertyValue
49 N05534ec2e3ca4d918ef44808b6a27d87 rdf:first Nbf3ff00c437f427fb494774d233b0a91
50 rdf:rest N6b3d7d8d2c4f429b9cf8fc0087414752
51 N0c9ed9c9e5ac4636ac42feea614a3ced rdf:first N19368cb2e37f405bb0de5973f2cb4a73
52 rdf:rest Nbb5654fad21e4d01adf3619ce71902ad
53 N0ce69bcae7a04ba6b518a2bdf581bb47 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
54 schema:familyName Richardson
55 schema:givenName Paul G.
56 rdf:type schema:Person
57 N11752d75c70f49648c53b331b9d69cdc schema:volumeNumber 9
58 rdf:type schema:PublicationVolume
59 N13f3fa4ac07f44d7a13ce4bcceee7e0b schema:affiliation https://www.grid.ac/institutes/grid.418019.5
60 schema:familyName Hoos
61 schema:givenName Axel
62 rdf:type schema:Person
63 N1536c36f27f24752bb129edd7a4c6b63 schema:issueNumber 4
64 rdf:type schema:PublicationIssue
65 N173ec1dd110f43aeb845caa85fb6c4ec schema:affiliation https://www.grid.ac/institutes/grid.418019.5
66 schema:familyName Bragulat
67 schema:givenName Veronique
68 rdf:type schema:Person
69 N19368cb2e37f405bb0de5973f2cb4a73 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
70 schema:familyName Reeves
71 schema:givenName Brandi
72 rdf:type schema:Person
73 N3c5957be966e4f9c9f7fe8bbb10f9e36 rdf:first N173ec1dd110f43aeb845caa85fb6c4ec
74 rdf:rest Nd0c87bea3a614275b36e873793a5d953
75 N3ff744e757924c6ab1d86cd47a049d42 schema:affiliation https://www.grid.ac/institutes/grid.418019.5
76 schema:familyName Opalinska
77 schema:givenName Joanna B.
78 rdf:type schema:Person
79 N4e6151b7860244fd92e90dba31b71e69 schema:affiliation https://www.grid.ac/institutes/grid.415224.4
80 schema:familyName Trudel
81 schema:givenName Suzanne
82 rdf:type schema:Person
83 N4e8045e63cf842188d98c2773776f61a rdf:first Nbf275ae3241146439a8b8d7e08c90e57
84 rdf:rest rdf:nil
85 N5105b30bde8e4a5dacd164e21849a05a schema:affiliation https://www.grid.ac/institutes/grid.418019.5
86 schema:familyName He
87 schema:givenName Zangdong
88 rdf:type schema:Person
89 N55334aa4518e451896ef4f616a43d4f2 schema:affiliation https://www.grid.ac/institutes/grid.468189.a
90 schema:familyName Voorhees
91 schema:givenName Peter M.
92 rdf:type schema:Person
93 N5aa087379eec484aa567d906e4856c49 schema:affiliation https://www.grid.ac/institutes/grid.418019.5
94 schema:familyName Gupta
95 schema:givenName Ira
96 rdf:type schema:Person
97 N5e55c243287a420e83fbec7c0a7e9601 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
98 schema:familyName Libby
99 schema:givenName Edward N.
100 rdf:type schema:Person
101 N644251325918431480e24c6c96d0dd07 rdf:first N0ce69bcae7a04ba6b518a2bdf581bb47
102 rdf:rest Nc8aad80385234eb49ff3747e6ef39da6
103 N6b3d7d8d2c4f429b9cf8fc0087414752 rdf:first Ndbe24170b53f43c682472a378d98f122
104 rdf:rest Nb82089827b7c4a7dbb2535e0aa7b8a8a
105 N7c70ca36b163492880686d8982e24383 schema:name doi
106 schema:value 10.1038/s41408-019-0196-6
107 rdf:type schema:PropertyValue
108 N86cf05e2233f4e128467535b377b9e37 schema:name readcube_id
109 schema:value d7e590022e3cb949c344077c15f2dbc187151c32556ce77ec0054bbd94ab8605
110 rdf:type schema:PropertyValue
111 N9f8ce41b1d6443318fa2a5387f07bca4 rdf:first N5aa087379eec484aa567d906e4856c49
112 rdf:rest N3c5957be966e4f9c9f7fe8bbb10f9e36
113 Na6ecd2d8796840228ac8cc5bfc3534ef schema:name nlm_unique_id
114 schema:value 101568469
115 rdf:type schema:PropertyValue
116 Nb7031f635c9e4cc2ac7d4d2946e327a7 schema:name dimensions_id
117 schema:value pub.1112880630
118 rdf:type schema:PropertyValue
119 Nb80875ec3c4d4bb5bc969678ecce7e8f schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 Nb82089827b7c4a7dbb2535e0aa7b8a8a rdf:first N55334aa4518e451896ef4f616a43d4f2
122 rdf:rest N0c9ed9c9e5ac4636ac42feea614a3ced
123 Nbb5654fad21e4d01adf3619ce71902ad rdf:first N5e55c243287a420e83fbec7c0a7e9601
124 rdf:rest N644251325918431480e24c6c96d0dd07
125 Nbdfd925582ec442b9fe333a332c2c39f rdf:first N3ff744e757924c6ab1d86cd47a049d42
126 rdf:rest N4e8045e63cf842188d98c2773776f61a
127 Nbf275ae3241146439a8b8d7e08c90e57 schema:affiliation https://www.grid.ac/institutes/grid.25879.31
128 schema:familyName Cohen
129 schema:givenName Adam D.
130 rdf:type schema:Person
131 Nbf3ff00c437f427fb494774d233b0a91 schema:affiliation https://www.grid.ac/institutes/grid.5386.8
132 schema:familyName Lendvai
133 schema:givenName Nikoletta
134 rdf:type schema:Person
135 Nc8aad80385234eb49ff3747e6ef39da6 rdf:first N13f3fa4ac07f44d7a13ce4bcceee7e0b
136 rdf:rest N9f8ce41b1d6443318fa2a5387f07bca4
137 Nd0c87bea3a614275b36e873793a5d953 rdf:first N5105b30bde8e4a5dacd164e21849a05a
138 rdf:rest Nbdfd925582ec442b9fe333a332c2c39f
139 Ndbe24170b53f43c682472a378d98f122 schema:affiliation https://www.grid.ac/institutes/grid.451052.7
140 schema:familyName Popat
141 schema:givenName Rakesh
142 rdf:type schema:Person
143 Ne628ea020d484189a3306e842ba5dcd1 rdf:first N4e6151b7860244fd92e90dba31b71e69
144 rdf:rest N05534ec2e3ca4d918ef44808b6a27d87
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
149 schema:name Clinical Sciences
150 rdf:type schema:DefinedTerm
151 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1038/s41408-019-0196-6
152 rdf:type schema:MonetaryGrant
153 sg:journal.1045682 schema:issn 2044-5385
154 schema:name Blood Cancer Journal
155 rdf:type schema:Periodical
156 sg:pub.10.1038/leu.2008.402 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028476811
157 https://doi.org/10.1038/leu.2008.402
158 rdf:type schema:CreativeWork
159 sg:pub.10.1038/leu.2013.313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026245496
160 https://doi.org/10.1038/leu.2013.313
161 rdf:type schema:CreativeWork
162 sg:pub.10.1038/leu.2016.388 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037474750
163 https://doi.org/10.1038/leu.2016.388
164 rdf:type schema:CreativeWork
165 sg:pub.10.1038/leu.2017.138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086041207
166 https://doi.org/10.1038/leu.2017.138
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/s1470-2045(18)30576-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1109823387
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1056/nejmoa1506348 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002559520
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1084/jem.20031330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002726623
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1089/jop.2015.0064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059285427
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1093/annonc/mdx096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084601874
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1111/bjh.14145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007909090
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1111/j.1365-2141.2012.09241.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1044999235
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1111/nyas.13038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021804241
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1158/1078-0432.ccr-12-2422 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018678117
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1182/blood-2010-10-299487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029457945
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1182/blood-2013-10-535088 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018796721
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1200/jco.2018.36.15_suppl.8007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106715820
191 rdf:type schema:CreativeWork
192 https://doi.org/10.18632/oncotarget.25359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104240051
193 rdf:type schema:CreativeWork
194 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
195 schema:name Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.25879.31 schema:alternateName University of Pennsylvania
198 schema:name Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
201 schema:name University of Washington, Seattle, WA, USA
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.415224.4 schema:alternateName Princess Margaret Cancer Centre
204 schema:name Princess Margaret Cancer Centre, Toronto, ON, Canada
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.418019.5 schema:alternateName GlaxoSmithKline (United States)
207 schema:name GSK, Philadelphia, PA, USA
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.451052.7 schema:alternateName National Health Service
210 schema:name NIHR/University College London Hospital Clinical Research Facility, NHS Foundation Trust, London, UK
211 rdf:type schema:Organization
212 https://www.grid.ac/institutes/grid.468189.a schema:alternateName Levine Cancer Institute
213 schema:name Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
214 rdf:type schema:Organization
215 https://www.grid.ac/institutes/grid.5386.8 schema:alternateName Cornell University
216 schema:name Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
217 Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
220 schema:name Dana-Farber Cancer Institute, Boston, MA, USA
221 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...